Merck’s (MRK) Animal Health division announced the FDA approval of Bravecto Quantum – a new, once-yearly injectable product to treat and protect dogs from fleas and ticks. The product is expected to be available at veterinary clinics and hospitals nationwide by August. Bravecto Quantum was first approved in Australia and New Zealand in 2023, followed by the EU in 2024 and now the U.S. in 2025. In total, Bravecto Quantum is currently approved in more than 50 countries worldwide. Bravecto Quantum kills adult fleas and is indicated for the treatment and prevention of flea infestations and for the treatment and control of tick infestations, Dermacentor variabilis and Rhipicephalus sanguineus.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck price target lowered to $98 from $99 at Morgan Stanley
- Verona Pharma downgraded to Hold from Buy at Truist
- Merck’s doravirine/islatravir NDA in HIV-1 accepted by FDA
- Merck & Company’s Strategic Acquisition of Verona Pharma: Balancing Long-Term Gains with Short-Term Financial Adjustments
- Merck’s Strategic Acquisition of Verona Pharma: Enhancing Respiratory Portfolio Amidst Keytruda Competition